Reported 1 day ago
Billionaire Ken Griffin has significantly increased Citadel's investment in Viking Therapeutics by $93 million, as Wall Street analysts predict a potential 105% stock price surge. Analysts are optimistic about Viking's clinical-stage drug VK2735, which targets appetite suppression like the successful treatments from Eli Lilly and Novo Nordisk. While the market awaits further trial results, Griffin's investment positions him ahead in the growing demand for weight management drugs.
Source: YAHOO